Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomarkers Improve Odds Of Approval, BIO Study Finds

Executive Summary

BIO/Biomedtracker analysis strengthens the case for expanded use of drug development tools like biomarkers with finding that well-defined patient populations in clinical trials are associated with greater likelihood of approval.

You may also be interested in...



Myriad Builds Case For Personalized Prescribing Of Rheumatoid Arthritis Drugs

Data presented at the American College of Rheumatology meeting show that not everybody needs a biologic, and that biomarker testing could enable more cost-effective use, says Myriad subsidiary Crescendo.

Pharma R&D Productivity Shows Signs Of Progress

It now takes 13 drugs in Phase I to yield one marketed drug, compared to 19 in 2007 to 2011, according to new data from KMR Group.

Biomarkers Qualification: Can FDA Get Rolling Before A Push From Congress?

FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057668

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel